Natco Pharma

Which are the latest news on Natco Pharma?

Why is Natco Pharma Ltd. falling/rising?

As of 23-Jun, Natco Pharma Ltd. is seeing its stock price rise to 892.95, up 0.97%, driven by strong fundamentals, positive sector performance, and increased institutional holdings, despite a 24.8% decline in profits over the past year. The stock's resilience and attractive valuation further support investor confidence.

As of 23-Jun, Natco Pharma Ltd. is experiencing a rise in its stock price, currently at 892.95, with a change of 8.6 (0.97%) upwards. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.41% today, indicating a positive performance relative to its peers. Additionally, the stock reached an intraday high of Rs 913, reflecting a 3.24% increase at its peak during the trading day.<BR><BR>Moreover, the company exhibits strong fundamentals, including high management efficiency with a return on equity (ROE) of 16.51% and being net-debt free, which can instill confidence among investors. The stock is also trading at a fair value compared to its peers, with an attractive valuation indicated by a price to book value of 1.7. Furthermore, institutional holdings are robust at 22.83%, having increased by 2.28% over the previous quarter, suggesting that knowledgeable investors are confident in the company's prospects.<BR><BR>Despite a significant decline in profits over the past year by 24.8%, the stock has still managed to generate a return of 2.88%. This resilience, combined with the positive performance metrics today, contributes to the upward movement in Natco Pharma Ltd.'s stock price.

How big is Natco Pharma?

As of 10th June, Natco Pharma Ltd. has a market capitalization of 15,545.00 Cr, with recent net sales of 4,078.30 Cr and a net profit of 1,418.50 Cr. The company's shareholder's funds are 7,607.00 Cr, and total assets amount to 8,580.70 Cr.

As of 10th June, Natco Pharma Ltd. has a market capitalization of 15,545.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Natco Pharma reported Net Sales of 4,078.30 Cr and a Net Profit of 1,418.50 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 7,607.00 Cr and Total Assets of 8,580.70 Cr.

Who are in the management team of Natco Pharma?

The management team of Natco Pharma includes V C Nannapaneni (Managing Director), G S Murthy (Chairman), Rajeev Nannapaneni (CEO), and several independent directors, along with key vice presidents and the company secretary, all responsible for guiding the company's strategic direction and operations.

The management team of Natco Pharma includes the following key individuals:<BR><BR>1. **V C Nannapaneni** - Managing Director<BR>2. **G S Murthy** - Chairman & Independent Director<BR>3. **Rajeev Nannapaneni** - Director & Chief Executive Officer<BR>4. **T V Rao** - Non-Executive & Independent Director<BR>5. **D G Prasad** - Non-Executive & Independent Director<BR>6. **Leelaa Digumarti** - Non-Executive & Independent Director<BR>7. **PSRK Prasad** - Vice President & Director<BR>8. **MUR Naidu** - Non-Executive & Independent Director<BR>9. **D Linga Rao** - President & Director<BR>10. **Pavan Bhat** - Vice President & Director<BR>11. **Venkat Ramesh** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in steering the company's strategic direction and operations.

Who are the peers of the Natco Pharma?

Natco Pharma's peers include Granules India, ERIS Lifescience, Caplin Point Lab, Cohance Life, Jubilant Pharma, Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma. Most peers exhibit below-average growth, with Granules India showing the highest 1-year return at 45.70%, while Natco Pharma's return is -6.51%.

Peers: The peers of Natco Pharma are Granules India, ERIS Lifescience, Caplin Point Lab, Cohance Life, Jubilant Pharmo, Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Granules India, Caplin Point Lab, Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma, while Good management risk is found at ERIS Lifescience, Cohance Life, Jubilant Pharmo, and the rest. Average management risk is noted at Cohance Life and Jubilant Pharmo. All peers exhibit Below Average growth, with Granules India, ERIS Lifescience, Caplin Point Lab, Cohance Life, Jubilant Pharmo, Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma showing this characteristic. Excellent capital structure is present in Granules India, Caplin Point Lab, Cohance Life, Alembic Pharma, Concord Biotech, Alivus Life, and Marksans Pharma, while Good capital structure is found at ERIS Lifescience and Jubilant Pharmo.<BR><BR>Return Snapshot: Granules India has the highest 1-year return at 45.70%, while Cohance Life has the lowest at -57.72%. Natco Pharma's 1-year return is -6.51%, which is significantly lower than Granules India but higher than Cohance Life. Additionally, ERIS Lifescience, Jubilant Pharmo, Alembic Pharma, Concord Biotech, and Cohance Life have negative six-month returns.

What does Natco Pharma do?

Natco Pharma Ltd. is a small-cap pharmaceutical company focused on developing and manufacturing pharmaceutical products, with a market cap of INR 15,545 Cr and reported net sales of 739 Cr and net profit of 268 Cr for March 2026. The company has a P/E ratio of 11.00 and a dividend yield of 0.58%.

Overview: <BR>Natco Pharma Ltd. is a small-cap company operating in the Pharmaceuticals & Biotechnology industry, focusing on the development and manufacturing of pharmaceutical products.<BR><BR>History: <BR>Natco Pharma Limited was originally incorporated on 19 September 1981 as 'Natco Fine Pharmaceuticals Private Limited'. The company changed its name to Natco Pharma Limited and received a fresh certificate of incorporation on 30 December 1994. The latest quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 739 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 268 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 15,545 Cr (Small Cap) <BR><BR>Key Metrics: <BR>P/E: 11.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.58% <BR>Debt-Equity: -0.15 <BR>Return on Equity: 15.38% <BR>Price to Book: 1.68 <BR><BR>Contact Details: <BR>Address: Natco House, Road No 2 Banjara Hills Hyderabad Telangana : 500033 <BR>Tel: 91-040-23547532 <BR>Email: investors@natcopharma.co.in <BR>Website: http://www.natcopharma.co.in

Should I buy, sell or hold Natco Pharma Ltd.?

Are Natco Pharma Ltd. latest results good or bad?

Natco Pharma Ltd.'s latest Q4 FY26 results show a net profit increase of 76.83% quarter-on-quarter, but a 34.11% decline year-on-year, alongside a concerning 39.47% drop in net sales compared to last year. Overall, while there are some positive quarterly trends, the company faces significant operational challenges and declining margins.

Natco Pharma Ltd.'s latest results for Q4 FY26 present a mixed picture. On one hand, the company reported a net profit of ₹267.90 crores, which is a significant increase of 76.83% quarter-on-quarter. However, this figure is down 34.11% year-on-year, indicating a decline compared to the same quarter last year. <BR><BR>Net sales also showed a sequential improvement of 14.18% from the previous quarter, reaching ₹739.10 crores. Yet, this represents a concerning year-on-year decline of 39.47%, which raises red flags about the company's operational health. <BR><BR>Moreover, the operating margin has dropped to 17.26%, marking a multi-quarter low and reflecting significant margin compression. The company's reliance on a tax reversal of ₹89.20 crores to boost profits further complicates the outlook, as it obscures the underlying operational weaknesses.<BR><BR>In summary, while there are some positive signs in terms of quarterly growth, the overall performance indicates significant challenges, particularly with revenue contraction and declining margins. Investors may view this as a cautious signal, suggesting that the company is facing substantial operational headwinds despite some short-term gains.

When is the next results date for Natco Pharma Ltd.?

The next results date for Natco Pharma Ltd. is 29 May 2026.

The next results date for Natco Pharma Ltd. is scheduled for 29 May 2026.

Has Natco Pharma Ltd. declared dividend?

Yes, Natco Pharma Ltd. has declared a dividend of 75% (₹1.5 per share) with an ex-date of February 18, 2026. While the company shows a strong total return of 57.75% over three years, shorter-term returns have been negative.

Natco Pharma Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 75%<BR>- Amount per share: 1.5<BR>- Ex-date: 18 Feb 26<BR><BR>Dividend Yield: 0.6%<BR><BR>Total Returns by Period:<BR>Over the 3-month period, the price return was -0.48%, the dividend return was 0.37%, resulting in a total return of -0.11%.<BR><BR>In the 6-month period, the price return was -9.07%, the dividend return was 0.57%, leading to a total return of -8.5%.<BR><BR>For the 1-year period, the price return was -15.54%, the dividend return was 0.60%, culminating in a total return of -14.94%.<BR><BR>During the 2-year period, the price return was -4.11%, the dividend return was 1.19%, resulting in a total return of -2.92%.<BR><BR>In the 3-year period, the price return was 53.95%, the dividend return was 3.80%, leading to a total return of 57.75%.<BR><BR>For the 4-year period, the price return was -10.84%, the dividend return was 3.07%, culminating in a total return of -7.77%.<BR><BR>In the 5-year period, the price return was -3.79%, the dividend return was 3.69%, resulting in a total return of -0.1%.<BR><BR>Overall, while Natco Pharma Ltd. has declared a substantial dividend, the total returns over various periods show a mixed performance, with significant negative returns in the shorter terms but a strong positive return over the longer three-year period.

Is Natco Pharma technically bullish or bearish?

As of December 3, 2025, Natco Pharma's trend is sideways with mixed signals: weekly indicators suggest mild bullishness while monthly indicators are bearish, indicating a lack of strong momentum.

As of 3 December 2025, the technical trend for Natco Pharma has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD and KST indicate a mildly bullish outlook, while the monthly MACD and KST are bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly. Daily moving averages are mildly bearish. Overall, the indicators suggest a lack of strong momentum in either direction, reflecting the sideways trend.

Is Natco Pharma overvalued or undervalued?

As of November 17, 2025, Natco Pharma is considered an attractive investment opportunity, trading at a PE ratio of 9.55 and showing potential for growth with favorable valuation metrics compared to peers, despite recent underperformance against the Sensex.

As of 17 November 2025, Natco Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.55, an EV to EBIT of 7.93, and a ROCE of 25.97%. These ratios suggest that Natco Pharma is trading at a discount compared to its peers, particularly when compared to Sun Pharma, which has a PE ratio of 36.69, and Divi's Lab, with a PE ratio of 69.78.<BR><BR>In the context of its peer group, Natco Pharma's valuation metrics stand out as more favorable, especially with a PEG ratio of 0.00, indicating potential for growth without the corresponding high valuation. While the stock has underperformed the Sensex over the past year, it has shown resilience with a 3-year return of 43.82%, suggesting that it may be positioned for recovery. Overall, Natco Pharma appears to be a compelling investment opportunity within the pharmaceuticals and biotechnology sector.

How has been the historical performance of Natco Pharma?

Natco Pharma has shown significant financial growth from March 2020 to March 2025, with net sales increasing from INR 1,915 crore to INR 4,429.50 crore, and profit after tax rising from INR 458.10 crore to INR 1,883.40 crore, reflecting improved operational efficiency and enhanced shareholder value. Total assets also grew from INR 4,587.80 crore to INR 8,580.70 crore during this period.

Answer:<BR>The historical performance of Natco Pharma shows significant growth in various financial metrics over the years.<BR><BR>Breakdown:<BR>Natco Pharma's net sales have steadily increased from INR 1,915.00 crore in March 2020 to INR 4,429.50 crore in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from INR 1,915.00 crore in March 2020 to INR 4,429.50 crore in March 2025. The company's operating profit (PBDIT) also saw substantial growth, climbing from INR 690.00 crore in March 2020 to INR 2,550.50 crore in March 2025, indicating improved operational efficiency. Profit before tax surged from INR 568.70 crore in March 2020 to INR 2,291.40 crore in March 2025, while profit after tax increased from INR 458.10 crore to INR 1,883.40 crore during the same period. The earnings per share (EPS) rose dramatically from INR 25.32 in March 2020 to INR 105.33 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from INR 4,587.80 crore in March 2020 to INR 8,580.70 crore in March 2025, with total liabilities increasing from INR 4,587.80 crore to INR 8,580.70 crore as well. Cash flow from operating activities improved significantly, reaching INR 1,696.00 crore in March 2025, compared to INR 417.00 crore in March 2020. Overall, Natco Pharma has demonstrated robust financial growth and operational performance over the years.

Who are the top shareholders of the Natco Pharma?

The top shareholders of Natco Pharma include promoter V C Nannapaneni with 15.66%, 54 mutual fund schemes holding 1.85%, and 292 foreign institutional investors (FIIs) with 17.49%. Individual investors own 23.68%, while the highest public shareholder is Belgrave Investment Fund at 2.31%, with no pledged promoter holdings.

The top shareholders of Natco Pharma include the promoters, with V C Nannapaneni being the individual with the highest holding at 15.66%. The company has a diverse shareholder base, with 54 mutual fund schemes collectively holding 1.85% and 292 foreign institutional investors (FIIs) holding 17.49%. Additionally, individual investors own 23.68% of the shares, and the highest public shareholder is Belgrave Investment Fund, which holds 2.31%. Overall, the majority of the shares are held by promoters, and there are no pledged promoter holdings.